Cookies help us to understand how you use our website so that we can provide you with the best experience when you are on our site. To find out more, read our privacy policy and cookie policy.
Manage Cookies
A cookie is information stored on your computer by a website you visit. Cookies often store your settings for a website, such as your preferred language or location. This allows the site to present you with information customized to fit your needs. As per the GDPR law, companies need to get your explicit approval to collect your data. Some of these cookies are ‘strictly necessary’ to provide the basic functions of the website and can not be turned off, while others if present, have the option of being turned off. Learn more about our Privacy and Cookie policies. These can be managed also from our cookie policy page.
Strictly necessary cookies(always on):
Necessary for enabling core functionality. The website cannot function properly without these cookies. This cannot be turned off. e.g. Sign in, Language
Analytics cookies:
Analytical cookies help us to analyse user behaviour, mainly to see if the users are able to find and act on things that they are looking for. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. Tools used: Google Analytics
Social media cookies:
We use social media cookies from Facebook, Twitter and Google to run Widgets, Embed Videos, Posts, Comments and to fetch profile information.
Civilian Utilization of Whole Blood, Leukocytes Reduced
The National Advisory Committee on Blood and Blood Products is conducting a survey of Canadian healthcare providers to gather perspectives on the non-military use of Whole Blood, Leukocytes Reduced in Canada.
In October 2022, Health Canada approved Whole Blood, Leukocytes Reduced to be manufactured and distributed by Canadian Blood Services (see FAQs for additional product information). However, this product will increase pressure on the blood supply, particularly products from Group O donors, and due to the limited evidence of clinical effectiveness, Whole Blood, Leukocytes Reduced is currently available only for military use.
A subcommittee of the National Advisory Committee on Blood and Blood Products has been formed to evaluate and plan for the non-military use of Whole Blood, Leukocytes Reduced and is seeking input from Canadian practitioners. Following ethics review, stakeholder input, and taking into account pragmatic considerations regarding supply, the NAC subcommittee will provide specific recommendations for the introduction of Whole Blood, Leukocytes Reduced for non-military use, including clinical versus research use, patient groups (pediatric, trauma, surgical, and pre-hospital) and monitoring of outcomes (utilization, wastage, safety, effectiveness, impact on utilization of other blood products).
To share your perspectives on Whole Blood, Leukocytes Reduced, please click on the survey link below. Registration is not required but is strongly encouraged using the registration link at the top right of the page.
The National Advisory Committee on Blood and Blood Products is conducting a survey of Canadian healthcare providers to gather perspectives on the non-military use of Whole Blood, Leukocytes Reduced in Canada.
In October 2022, Health Canada approved Whole Blood, Leukocytes Reduced to be manufactured and distributed by Canadian Blood Services (see FAQs for additional product information). However, this product will increase pressure on the blood supply, particularly products from Group O donors, and due to the limited evidence of clinical effectiveness, Whole Blood, Leukocytes Reduced is currently available only for military use.
A subcommittee of the National Advisory Committee on Blood and Blood Products has been formed to evaluate and plan for the non-military use of Whole Blood, Leukocytes Reduced and is seeking input from Canadian practitioners. Following ethics review, stakeholder input, and taking into account pragmatic considerations regarding supply, the NAC subcommittee will provide specific recommendations for the introduction of Whole Blood, Leukocytes Reduced for non-military use, including clinical versus research use, patient groups (pediatric, trauma, surgical, and pre-hospital) and monitoring of outcomes (utilization, wastage, safety, effectiveness, impact on utilization of other blood products).
To share your perspectives on Whole Blood, Leukocytes Reduced, please click on the survey link below. Registration is not required but is strongly encouraged using the registration link at the top right of the page.